CLINICAL DEEP-DIVE · THE DIALYSIS POPULATION

Obesity in the dialysis patient: hemodialysis and peritoneal dialysis

On dialysis, obesity stops behaving the way it does in earlier CKD. Survival associations invert, the scale stops meaning what it usually means, and peritoneal dialysis adds its own glucose load. Reading obesity correctly here is a distinctly nephrological skill.

The obesity paradox — and how to read it

In maintenance hemodialysis, a higher BMI is repeatedly associated with lower mortality — the reverse of the general population. The likely explanation is not that adiposity protects, but that BMI in this cohort largely tracks muscle mass and nutritional reserve, and that protein-energy wasting is the real driver of death. The practical lesson is not to encourage weight gain, but to avoid reflexive weight-loss goals on dialysis and to distinguish, in every patient, fat excess from the preserved muscle that is actually protective.

Body composition, not the scale

BMI and bioimpedance are unreliable against fluid overload; interdialytic weight change is volume, not adiposity. Assessing obesity in a dialysis patient means reading body composition through fluid shifts — a skill that belongs to nephrology — and setting the dry weight before any statement about “weight” can be trusted.

Peritoneal dialysis: the glucose load

PD adds a modality-specific problem. Continuous glucose absorption from conventional dextrose dialysate is associated with a gain in fat mass and a loss of lean mass, and contributes to weight gain, dyslipidemia, and metabolic syndrome. Glucose-sparing strategies — notably icodextrin for the long dwell — can attenuate fat accumulation and improve volume management, and belong in the obesity-conscious PD prescription.

Weight-loss pharmacotherapy on dialysis

GLP-1 and dual-agonist drugs are not renally cleared, so dialysis does not mandate dose reduction. But the evidence base at eGFR <15 and on dialysis is thin and largely off-label, and the safety calculus shifts: in the anuric patient, dehydration-driven AKI is not the concern it is in earlier CKD, while hypoglycemia (with concurrent insulin or secretagogues), gastroparesis layered on uremia, and volume/blood-pressure effects move to the foreground. Titrate cautiously, individualize, and document the evidence gap honestly.

Why it matters: the transplant gate

For many dialysis patients the reason to address obesity is access to transplantation, where BMI thresholds still gate listing. That links this problem directly to candidacy — treated in the companion deep-dive — and reframes dialysis-phase weight management as a step toward the waitlist, not an end in itself.

Related on Nephrobesity

Clinician: Obesity in the kidney transplant candidate · Curriculum → The dialysis population. Patient-facing: Can I take Ozempic on dialysis?

Key evidence

  1. Reverse epidemiology of the obesity paradox in dialysis: fact or fiction? Physiol Rep. 2024;12(21):e70107. PubMed ↗
  2. Glucose absorption from peritoneal dialysate is associated with a gain in fat mass and a reduction in lean body mass in prevalent PD patients. Br J Nutr. 2020;123(11):1269–1276. PubMed ↗
  3. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients. Nephrol Dial Transplant. 2010;25(2):593–599. PubMed ↗
  4. ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. J Am Soc Nephrol. 2024;35(11):1574–1588. PubMed ↗

⚠︎ Educational, for professional discussion only. This page summarizes evidence for clinicians and is not individual medical advice or a treatment protocol. Citations are evidence anchors; verify current data before formal use. Nephrobesity is an independent educational resource and curriculum, not a board specialty, subspecialty, or medical society.